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Abstract
Cancer stem cells (CSCs) are considered a subset of the bulk tumor responsible for initiating and maintaining the disease.
Several surface cellular markers have been recently used to identify CSCs. Among those is CD133, which is expressed by
hematopoietic progenitor cells as well as embryonic stem cells and various cancers. We have recently isolated and cultured
CD133 positive [CD133(+)] cells from various cancer cell lines using a NASA developed Hydrodynamic Focusing Bioreactor
(HFB) (Celdyne, Houston, TX). For comparison, another bioreactor, the rotary cell culture system (RCCS) manufactured by
Synthecon (Houston, TX) was used. Both the HFB and the RCCS bioreactors simulate aspects of hypogravity. In our study,
the HFB increased CD133(+) cell growth from various cell lines compared to the RCCS vessel and to normal gravity control.
We observed a (+)15-fold proliferation of the CD133(+) cellular fraction with cancer cells that were cultured for 7-days at
optimized conditions. The RCCS vessel instead yielded a (2)4.8-fold decrease in the CD133(+)cellular fraction respect to the
HFB after 7-days of culture. Interestingly, we also found that the hypogravity environment of the HFB greatly sensitized the
CD133(+) cancer cells, which are normally resistant to chemo treatment, to become susceptible to various
chemotherapeutic agents, paving the way to less toxic and more effective chemotherapeutic treatment in patients. To
be able to test the efficacy of cytotoxic agents in vitro prior to their use in clinical setting on cancer cells as well as on cancer
stem cells may pave the way to more effective chemotherapeutic strategies in patients. This could be an important
advancement in the therapeutic options of oncologic patients, allowing for more targeted and personalized chemotherapy
regimens as well as for higher response rates.
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Introduction
Neoplasms may be viewed as tissue consisting of a heteroge-
neous population of cells that differ in biological characteristics
and potential for self-renewal [1]. The clonal nature of certain
malignant tumors is well established [2]. According to the model of
clonal evolution of tumor cells, cancer is formed through the
accumulation of genetic changes in cells and gradual selection of
clones [3,4]. Therefore, the tumor is regarded as abnormal tissue
that descended from a single cell through continuous accumula-
tion of genetic errors and various epigenetic changes. However,
several experiments carried out during the last decades have
shown that not every tumor cell is a tumor initiating cell (T-IC)
and that as many as 10
6 murine or human tumor cells are required
to transplant a new tumor from an existing one [4,5,6,7]. This
evidence suggested the possibility that tumor cells may exist in a
hierarchical state in which only a small number of cells possess
tumor initiating potential. Recent data from both hematologic
malignancies and solid tumors have suggested that there are only
minor populations of cells in each malignancy that are capable of
tumor initiation which are the cancer stem cells (CSC)
[4,5,6,7,8,9,10,11,12,13,14,15]. These cells appear to be capable
of asymmetric division and self-renewal, and are only a minor
fraction among the bulk of more differentiated cells in the tumor
[16,17,18].
Recently, CSCs have been studied in different primary tumor
types in order to develop CSC-specific therapies [6,11,19,20,21].
Interestingly, certain tumors are highly resistant to chemotherapy
and other forms of treatment and although aggressive treatments
destroy the majority of the cancerous cells, a small fraction of the
cells survive and often regenerate into even larger masses of tumor
cells [22,23,24]. Effective therapies for cancer patients require a
thorough understanding of mechanisms leading to tumor
development and drug resistance.
The recent discovery of CSCs has played a pivotal role in
changing our view of carcinogenesis and chemotherapy. CSCs are
thought to be responsible for the formation and growth of
neoplastic tissue. The CSCs are naturally resistant to most current
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why traditional chemotherapies can initially reduce the majority of
the tumor bulk but fail to eradicate it in full, allowing eventual
recurrence [1,11,17,18,22]. CSCs are more resistant to therapy
not only secondary to quiescence, but also due to increased
expression of anti-apoptotic proteins and drug efflux transporters.
Cancer treatments available today mostly exploit the proliferative
and metastatic potentials of the cancer cells; therefore, the
majority of treatments are targeted at rapidly dividing cells and
at molecular targets that represent the bulk of the tumor. This may
explain the failure of treatments to eradicate the disease or to
prevent recurrence of cancer. Additionally, if a drug affects the
growth of only a minor population of cells, there will be only a
minimal decrease in the growth of the tumor in the short term.
Theoretically, identification and characterization of the CSCs
may allow the development of treatment modalities that target the
cancer stem cells rather than the rapidly dividing cells in the
cancer.
Prolonged exposure of humans and experimental animals to the
altered gravitational conditions of space flight has adverse effects
on different cellular systems. The effects of hypogravity environ-
ment on tumor growth and carcinogenesis are yet unknown and
this research field still lacks systematic investigation on hypogravity
induced gene expression, which is the key information needed to
ultimately unfold the mechanism behind hypogravity-induced
diseases. To this end, we have studied the effects of simulated
hypogravity on human osteosarcoma cells cultured in the NASA-
developed hydrofocusing bioreactor (HFB) and in the rotary cell
culture system (RCCS). Various designs of rotating-wall vessels
have been used to create a three-dimensional culture environment
with variable shear stress and hypogravity simulating that in space
[25]. The HFB (Celdyne, Houston, TX) developed by NASA at
the Johnson Space Center, is a fluid filled dome, which rotates at a
specified speed and has a conical spinner to provide a unique
hydrofocusing capability that will allow for an extremely low-shear
culture environment and a nylon gas transfer membrane [25]. The
RCCS consists of a horizontally rotated culture vessel oxygenated
by a flat silicone rubber gas transfer membrane [26]. The NASA-
designed HFB bioreactor and the RCCS have been successfully
used on Earth and in Space to enable investigators to use modeled
or actual hypogravity, respectively, to study the role of gravity on
the formation of three-dimensional mammalian cell tissue models
and production of bio-products [25,27,28,29,30,31].
In this study we show that cancer stem cells are stimulated to
proliferate when they are cultured in the hypogravity conditions
produced by the HFB and that the reduction of gravity simulated
in the HFB sensitizes CSCs to chemotherapeutic agents.
Results
Osteosarcoma stem-like cells proliferate in the Hydro-
Focusing Bioreactor (HFB), but not in rotary cell culture
system (RCCS)
Modeled hypogravity is a condition in which cells are in
constant free fall and in which they are able to grow in an
anchorage independent manner. Since the effects of hypogravity
on tumors are unknown, we thought to investigate the effects of
modeled hypogravity in the absence of shearing stress on the
growth capacity of tumor cells of different embryonic origin. We
have used an HFB developed by NASA at the Johnson Space
Center, which is composed of a 50 mL fluid filled dome that
rotates at a specified speed and that has an internal conical spinner
that hydro-focuses the cell culture allowing for a low-shear
environment.
To our surprise, we found that when a known number of
SAOS-2 cells were seeded in the HFB, only a small fraction of
these cells survived the treatment, independently from the cellular
density seeded in the bioreactor. Figure 1A shows that the
number of viable SAOS-2 cells cultured for 5-days in the HFB was
dramatically reduced.
Interestingly, SAOS-2 cells cultured in the bioreactor formed
cell spheres and appeared to be significantly smaller than SAOS-2
cells cultured in dishes and harvested by trypsin treatment (data
not shown). Figure 1B shows a 206bright field picture of spheres
formed from SAOS-2 cells that were grown in the HFB for 5 days.
Cells were removed from the HFB reactor and pictures were taken
immediately using an inverted microscope using contrast phase.
Because of their apparent change in morphology and ability to
form spheres in the HFB environment and because others have
demonstrated the presence of CD133(+) cells within primary bone
sarcomas, as well as the osteosarcoma cell lines MG-63, OS-521,
0S-01-187, OS-99-01, and SAOS-2 and the chondrosarcoma cell
line CS-828 [32,33], we hypothesized that the HFB selected cells
were CD133(+). To test this hypothesis we immunophenotyped
these cells with an antibody directed against CD133 (Miltenyi,
Germany), and found that HFB selected cells were 100% positive
to CD133, a typical stem cell marker of mesenchymal origin
(Figure 1B, inset panel and Figure 1C). Since the SAOS-2
cells recovered from the bioreactor were all CD133(+) (98.8%)
(Figure 1C), we wanted to determine whether the CD133(+) cells
not only survived but also proliferated in the hypogravity
environment. To this end, we selected CD133(+) cells from the
SAOS-2 or HOS cell lines using a MACSorting system and
challenged these CD133(+) cells to a 5-day run in the HFB.
Interestingly, SAOS-2 or HOS cells MACSorted with an antibody
against CD133 and cultured in the bioreactor for 5 days increased
in number by two-fold (Figure 1A). Figure 1A shows the trypan
blue exclusion cell counts of CD133(+) SAOS-2 viable cells
recovered after 5 days of culture in the bioreactor.
After a few trials of cell culture optimization, we were able to
achieve a 15-fold increase in proliferation of CD133(+) cancer
stem-like cells from the parental SAOS-2 cells over a seven-day
period by stopping the reactor every 24-hours and gently mixing
the culture 10 times in an orthogonal manner over a period of one
minute, which allowed for redistribution of the media in the dome
and mixing of the nutrient with the proliferating cells (Figure 1D).
Figure 1D shows that following an optimized protocol of cell
culture in the HFB, it is possible to select and to proliferate a
specific population contained in the SAOS-2 parental cell line.
Similar results were achieved using various other cancer cell lines
of different tissue origin and which express a variable amount of
the CD133 marker (HOS, U2OS, T98G, U87MG, Du145,
LNCap, WI38, H23, Hep3b, Hela, Mewo, HO-1 cells, HN12 and
HN30), see Table 1, and data not shown.
Another bioreactor that simulates hypogravity, the 50 mL
rotary cell culture system (RCCS) [26] manufactured by
Synthecon (Houston, TX), was used to compare results generated
using the HFB. In a parallel experiment in which we seeded an
equal number of SAOS-2 cells in the same tissue culture incubator
with identical conditions of rotor speed, CO2, temperature, and
vessel volume (50 mL), the HFB increased CD133(+) cell growth
from SAOS-2 cells compared to the RCCS vessel and to earth
gravity control. 5610
‘6 SAOS-2 cells were seeded in the HFB or
RCCS bioreactors of which 350,000 (7%) were CD133(+) and
4,650,000 CD133(2)( Table 2). Culture media, oxygenation,
speed, temperature and CO2 were kept consistently constant for
the two culture systems and in the same incubator for a 7-days run.
After a 7-day run, the vessels were harvested and cells were reacted
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Germany) and counted using a BD Facs Aria flow cytometer.
An isotype antibody was used as control. From the comparison of
the two bioreactor cultures, we showed that a (+)15-fold increase in
CD133(+) cells number (5,370,960 CD133+ cells) was achieved
using the HFB on a 7-day run. No proliferation of CD133(+) cells
was observed in the culture derived from the RCCS culture vessel.
The RCCS culture vessel showed instead a drastic reduction in the
CD133(+) cell population [(2)4.8 fold decrease] from the number
of CD133(+) cells seeded in the bioreactors on day-0 (Table 2). In
fact, the number of SAOS-2 CD133(+) cells decreased from
350,000 to 72,800 in a 7-day run in the RCCS, while the HFB
grown SAOS-2 CD133(+) cells increased from 350,000 to
5,370,960 during an equivalent period of time.
Because of this dramatic difference in the growth of SAOS-2
CD133(+) cells in the two bioreactors generating hypogravity
(HFB and RCCS), we wanted to verify if pH could be a variable
causing the effects on cell growth observed. Therefore, we
measured the pH of the media of the HFB and RCCS bioreactors
kept in the same incubator with a CO2 level set at 5% and a
constant temperature of 37uC before and after a run of 7-days. We
compared the pH of the media from the HFB and RCCS vessels
with the conditioned media of control cells grown in a Petri dish in
earth gravity condition versus unspent D-MEM medium. No
statistically significant difference was found among the different
cell culture conditions by repeating the experiments three times. In
fact, unspent medium showed a pH of 7.8260.04. Medium from
control SAOS-2 cells grown in a Petri dish in normal gravity
conditions showed a pH of 7.9660.23; medium from SAOS-2
cells grown in the HFB had a pH of 7.7160.23; and medium from
SAOS-2 cells grown in the RCCS bioreactor showed a pH of
7.960.11, demonstrating that the different growth of CD133(+)
Figure 1. CD133(+) SAOS-2 cells are selected in the hydrofocusing bioreactor. A) Trypan blue exclusion cell count of SAOS-2 cells
(osteosarcoma cells) and SAOS-2 cells cultured in the HFB, CD133(+) SAOS-2 cells and CD133(+) SAOS-2 cells cultured in the HFB, and of CD133(+)
SAOS-2 cells and CD133(+) SAOS-2 cells cultured in normal gravity condition. Gray bars indicate the number of cells placed in the control on day-1.
Black bars indicate the number of viable cells recovered after 5 days of culture in that culturing condition. B) Bright field contrast phase image (206)
of 3-D culture (spheres) formed from SAOS-2 cells that were grown in the HFB for 5 days. Inset (top right) shows an image of CD133
immunofluorescence staining of SAOS-2 cells grown in the bioreactor for 5-days. C) Flow cytometry chart of the CD133 immunophenotype of SAOS-2
cells. An isotype antibody was used as a control. D) Trypan blue exclusion cell counts of an optimized experiment of HFB culture of SAOS-2 cells in the
HFB after seven days. CD133(+) SAOS-2 cells cultured in the bioreactor were selected and proliferated 15-fold after seven days. White bar indicates
the number of SAOS-2 cells seeded in the HFB. Black bar indicates the number of viable CD133(+) SAOS-2 cells recovered after 7 days of optimized
culture in the bioreactor. Gray bar indicate the number of CD133(+) cells present in the parental SAOS-2 population. The data is representative of
three separate experiments yielding comparable results.
doi:10.1371/journal.pone.0010035.g001
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not due to changes in pH in the culturing media.
Osteosarcoma cells die by apoptosis in the Hydro-
Focusing Bioreactor (HFB)
Since only a small fraction of the osteosarcoma SAOS-2 as well
as HOS cells placed in the HFB cell culture system were recovered
after 3 or 5 days of culture, we tested whether these cells were
being eliminated from the initial population by causing them to
undergo apoptosis. Therefore, we compared the rates of apoptosis
of SAOS-2 cells cultured in the HFB for 3 and 5 days to
MACSorted CD133(+) cells cultured in the HFB for 3 and 5 days.
To this end we have analyzed SAOS-2 cells cultured for 3-days
or 5-days in the bioreactor and found that SAOS-2 cells cultured
in the HFB for 3 or 5-days die by apoptosis as shown by a flow
cytometric assay of Annexin-V and propidium iodide staining of
the samples (Figures 2 B and D). 24% of the cells were found in
apoptosis after 3-days of culture in the HFB. Interestingly, the
fraction of cells dying by apoptosis increased to 62% after 5-days
of culture in the HFB, confirming the initial observation
(Figure 1). Most importantly, samples of CD133(+) MACSorted
cells grown in the HFB for 5-days didn’t show such an increase in
apoptosis by Annexin V staining when compared to the control
sample (Figure 2E and F). In the same culture conditions in the
HFB, the CD133(+) cells proliferate while the CD133(2) cells
instead die by apoptosis.
We have also investigated this phenomenon by measuring the
activity of caspases by using a colorimetric caspases kit that
measures the activity of caspases-3 in the samples. According to
the data presented we found that SAOS-2 cells (total population)
cultured in the HFB for 5 days showed an increase of 1.6-fold in
the caspases-3 activity detected (Figure 2 G), which is a measure
of the apoptotic index in these cells.
Stem cell marker expression increases following culture
in the Hydro-Focusing Bioreactor
Perhaps the most intriguing capability conferred by the rotating,
low-shear bioreactor system is the opportunity to study, under
controlled conditions, the interaction of cells of a given type or the
interaction of one cell type with another when cells in suspension
are free to form their own associations. We wanted to analyze the
expression levels of various markers related to the development of
stem cells of mesenchymal origin. The expression of CD133,
CD34, CD38, Osteocalcin, Sparc, Sox-9, RunX-2, Stro-1,
CD117/c-Kit, Oct3/4, Endoglin, and Integrin-ß1 was examined
by flow cytometry. Figure 3A shows the percent of fluorescent
cells of the various markers examined in SAOS-2 cells cultured in
static condition and after culture in the HFB for 5-days. The
expression levels and the number of cells expressing the examined
markers increased after 5 days of culture in the HFB vessel
compared to the cells cultured in normal gravity conditions.
Interestingly, the SAOS-2 cells grown in the HFB vessel showed
the highest relative increase in the number of cells positive to Sox-
9, CD133, Osteocalcin, Integrin-ß1, Sparc, RunX-2, and
Endoglin (94.7%, 89.3%, 82%, 81.8%, 81.3%, 79%, and 76%,
respectively), when compared to SAOS-2 cells cultured under a
normal gravity conditions. Oct3/4, CD117, Stro-1, and CD34
also showed an increase in the number of cell number positivity
Table 1. Percentage of positivity 6 standard deviation to CD133 of the various cell lines tested.
Cell Line Tumor type % CD133 (+) %CD34(+) %CD38(+)
HOS Human osteosarcoma 37.767.8 5.5862.2 0.5260.07
SAOS-2 Human osteosarcoma 10.8666.8 1.1460.13 4.0860.08
U2OS Human osteosarcoma 1.0660.05 70.560.6 0.5160.06
T98G Human glioblastoma 0.360.1 0.460.2 0.260.01
U87MG Human glioblastoma 0.260.1 0.860.3 0.460.2
Du145 Human prostate adenocarcinoma 0.660.3 0.360.05 1.260.03
LNCap Human prostate adenocarcinoma 160.6 1.960.3 0.460.2
WI38 Human lung fibroblast 2.4611 . 6 60.5 0.560.2
H23 Human lung adenocarcinoma 5.3660.75 5.1861.1 0.460.13
Hep3b Human hepatocarcinoma 96.860.6 0.660.03 0.160.01
Hela Human cervical carcinoma 0.860.7 2.5610
Mewo Human melanoma 0.560.1 0 0
HO-1 Human melanoma 1.460.6 0.860.2 0.360.1
HN-12 Human H&N squamo cellular carcinoma 0.460.3 0.260.1 0.360.1
HN-30 Human H&N squamo cellular carcinoma 0.160.1 0.260.1 0.260.1
doi:10.1371/journal.pone.0010035.t001
Table 2. Comparison of CD133(+) and (2) cel counts 6 standard deviation of SAOS-2 cells grown in the HFB or RCCS vessels.
Device Total cell Input CD133(+) cell Input Total cell Output CD133(+) cell Output Fold Change
RCCS 5,000,000 350,000 5,200,000 72,800 (2) 4.8
HFB 5,000,000 350,000 5,370,960 5,370,960 (+) 15.3
doi:10.1371/journal.pone.0010035.t002
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growth versus SAOS-2 cells grown in simulated hypogravity for 5-
days. We found no change in the number of CD38 positive cells in
the same conditions. The experiment was repeated 5 times with
comparable results and standard deviations were calculated and
are reported on the diagram as error bars. Figure 3B shows an
example of immunofluorescence staining and positivity of SAOS-2
cells to CD133, Sox-9, Sparc, and CD117/c-Kit following growth
in the HFB vessel for 5 days.
CD133(+) cells grow three-dimensionally in the Hydro-
Focusing Bioreactor and form spheres
The SAOS-2 CD133(+) enriched osteosarcoma cells proliferate
and assemble three-dimensionally as sarcospheres after 3-days
culture in the bioreactor, which is yet another characteristic of
stem cell growth. Figures 4 A and B show at 10 and 406
magnification power, respectively, the sarcospheres grown in the
bioreactor after 3 days of culture in simulated hypogravity.
Interestingly, the CD133(+) SAOS-2 cells that were grown in
simulated hypogravity were able to re-establish the parental cell
line (constituted by about 10%66.8 CD133 (+) cells and 90%66.8
CD133(2) cells) after a period of one week when seeded into
treated culture dishes, which allow for adherent cells to attach to
the plastic environment. Figure 4 C and D (106 and 406,
respectively) show the SAOS-2 CD133(+) cells proliferated and
selected with the HFB that were subsequently grown in attaching
tissue culture dishes. In the reconstituted cell culture some not-
adhering cells were noticeable; these could be stem-like cells also
known as cancer stem cells.
It is known that stem-like cells will form cell spheres when
cultured in ultra low-attaching dishes. We therefore tested the
ability of CD133(+) SAOS-2 MAC-sorted cells to form cell clusters
if placed in ultra low-attaching dishes. Their ability to form
clusters was less efficient when compared to those cells that have
been cultured in the hydrofocusing bioreactor, but they were still
able to form spheres. Figure 5 A and B show spheres formed by
SAOS-2 CD133(+) cells in ultra low-attaching dishes. We also
tested the ability of the SAOS-2 CD133(+) MACSorted and
enriched cells to attach to tissue culture dishes and to reconstitute
the parental SAOS-2 cell line. As expected, the MACSorted
CD133(+) enriched cells placed in attaching tissue culture dishes
after being cultured in ultra low-attaching dishes for two weeks,
reconstituted the parental SAOS-2 cell line after one week of
culture by attaching to the dish, manifesting a flattened and
differentiated phenotype over time. Figure 5C and D shows
adherent SAOS-2 cells derived from CD133(+) MACSorted cells
grown in adherent tissue culture dishes. Figure 5 E shows the
SAOS-2 cell line reconstituted after 10-days of inoculation of
CD133(+) enriched cells in adhering tissue culture dishes.
An additional indication that two distinct populations are
identifiable in the SAOS-2 cell line is the evidence that CD133(+)
MACSorted SAOS-2 cells have enhanced ability to grow in soft
agar when compared to the parental cells. The cells were plated in
6-well plates performing 6 replicates of each experimental point.
Equal number of SAOS-2 cells and of CD133(+) SAOS-2 cells
(5610
3 cells/well) were seeded in 6 replicas into a six-well dish.
The efficiency of CD133(+) SAOS-2 cells to grow in soft agar and
to assemble in three-dimensional structures is much higher than
that of the parental SAOS-2 cells. Six hundred and forty 6240
colonies were counted from the soft-agar 6-well dishes seeded with
the CD133(+) SAOS-2 enriched cells compared to only 20612
colonies counted from the soft-agar dishes seeded with the
CD133(2) SAOS-2 cells. Interestingly, 120680 colonies were
counted from the soft-agar dishes seeded with the parental SAOS-
2 cells, suggesting that the ability of forming colonies in soft-agar
could be due to the presence of a fraction (consistently, about
10%66.8) of stem-like cells within the SAOS-2 cell line we have in
our laboratory (Table 3). Figure 6 shows an example of a soft-
agar assay performed with the parental tumor cell line (Figure 6A)
or with the CD133 (+) enriched fraction of SAOS-2 cells
(Figure 6B). The parental SAOS-2 cells formed spheres, but
with very low efficiency when compared to the enriched CD133
(+) cells.
Further evidence that there are two distinct populations in the
SAOS-2 cell line, which appears to be composed of CD133(+) and
(2) cells, is that these two different populations have a distinct cell
cycle profile. We performed a flow cytometry analysis of SAOS-2
cells grown in 1G culture and found that SAOS-2 CD133(+) cells,
which were sorted by their CD133 status and stained with
propidium iodide, had a different cell cycle profile with respect to
the CD133(+) population. Figure 6C shows a representative flow
cytometric assay of SAOS-2 cells demonstrating that the
CD133(2) SAOS-2 population had 13.8% of cells in the G2/M
phase of the cell cycle, while the CD133(+) cells showed an
increased fraction (49%) of cells in the G2/M phase of the cell
cycle. Comparable results were obtained in parallel and repeated
experiments.
Interestingly, SAOS-2 cells grown in the bioreactor for 5 days
and stained with an anti-CD133 (Miltenyi, Germany) and the
proliferation marker anti-Ki-67 demonstrated increased prolifer-
ation of the cells compared to the SAOS-2 cells grown in 1G
cultures. Figure 6D shows a representative flow cytometry assay
of SAOS-2 cells demonstrating that the cells cultured in the HFB
proliferate at a different rate than the total SAOS-2 cell
population. In fact, the fraction of SAOS-2 CD133(+) cells, which
are also positive to Ki-67, increased from 14.27% to 53.98%
comparing cells cultured in 1G-growth versus those cells cultured
for 5 days in HFB simulated hypogravity condition, respectively.
Comparable results were obtained in parallel and repeated
experiments.
Simulated hypogravity enhances apoptosis and
sensitizes cancer stem cells to chemotherapy
CSCs are thought to be responsible for initiating and
maintaining the disease. Some types of tumors are highly resistant
to chemotherapy and other forms of treatment. Although
aggressive treatments can destroy the majority of the cancerous
cells, a small fraction of them remain and often later regenerate
Figure 2. SAOS-2 cells die by apoptosis after 5 days of culture in the hydrofocusing bioreactor as evidenced by Annexin-V staining/
Facs analysis and caspases-3 colorimetric assay. A) Annexin-V staining of SAOS-2 cells cultured in 1-G for 3 days. The analysis allows to
distinguish in the diagram between living cells (lower left quadrant), early apoptotic cells (lower right quadrant), apoptotic cells (upper right
quadrant), and necrotic cells (upper left quadrant). B) Annexin-V staining of SAOS-2 cells cultured in the HFB for 3 days. C) Annexin-V staining of
SAOS-2 cells cultured in 1-G for 5 days. D) Annexin-V staining of SAOS-2 cells cultured in the HFB for 5 days. E) Annexin-V staining of CD133(+)
MACSorted SAOS-2 cells which were cultured in 1-G for 5 days. F) Annexin-V staining of CD133(+) MACSorted SAOS-2 cells which were cultured in the
HFB for 5 days. G) Relative caspase-3 activity of SAOS-2 cells (total population) cultured for 5 days in the HFB compared to SAOS-2 cells (total
population) grown in static 1G condition.
doi:10.1371/journal.pone.0010035.g002
Proliferation of CD133 Cells
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treatment resistant [17,18,20]. Our recent discovery that cancer
stem cells are stimulated to proliferate when they are placed in
hypogravity conditions encourages the idea to test the ability of
simulated hypogravity to sensitize tumor stem cells to chemother-
apeutic agents.
We have therefore tested the ability of hypogravity to sensitize
the osteosarcoma cells to various chemotherapy agents used in
cancer therapy. We have discovered that the HFB-hypogravity
environment sensitized the CD133(+) resistant osteosarcoma cells
to various chemotherapy agents at clinically relevant doses. We
have tested the sensitivity of osteosarcoma cells to cisplatin,
doxorubicin and methotrexate, which are the drugs of choice for
this tumor type in the clinical settings. SAOS-2 cells were grown
for 5-days in the HFB and then harvested. 1610
4 cells were plated
in 96-well dishes and were subjected, along with a comparable
number of cells of the other samples, to 5, 10, and 15 mg/mL of
cisplatin for 24 hours and then subjected to MTT assay
(Figure 7). The same numbers of cells were used for the
doxorubicin and methotrexate treatments. For methotrexate
treatments, the cells were subjected to 4, 11, 22, and 45 mg/mL
of methotrexate for 24 hours and then subjected to MTT assay.
For doxorubicin treatments the samples were treated with 0.5, 1.1,
and 2.2 mg/mL of doxorubicin for 24 hours and then subjected to
MTT assay. The MTT assay is a convenient colorimetric assay of
mitochondrial viability that assesses the number of viable cells
versus the number of dead cell in a given sample. Figures 7, 8,
and 9 show that the CD133(+) cells grown in the HFB increased
Figure 3. Fluorescence index of various stem cell and differentiation markers examined in cells cultured in 1-G static condition,
sorted by CD133 antibody or not, and after culture in the bioreactor for 5 days. A) Diagram of the expression levels of various bio-markers.
Lavender bars indicate the percentage of cells expressing basal levels of the various markers in parental SAOS-2 cells cultured in normal 1-G gravity
condition (control). Purple bars indicate the percentage of cells expressing the various markers in CD133(+) MACSorted SAOS-2 cells that were
isolated from parental SAOS-2 cells cultured in normal 1-G gravity condition. Yellow bars indicate the percentage of cells expressing the various
markers in CD133(+) MACSorted SAOS-2 cells that were cultured in hypogravity condition. Light blue bars indicate the percentage of cells expressing
the various markers in parental SAOS-2 cells that were cultured in hypogravity condition for 5-days, resulting in a population of selected and
proliferated CD133(+) SAOS-2 cells. B) Immunofluorescence staining (406) and positivity of SAOS-2 cells to CD133, Sox-9, SPARC, and CD117/c-Kit
following growth in the bioreactor for 5-days.
doi:10.1371/journal.pone.0010035.g003
Figure 4. Phase contrast images of spheres formed by HFB SAOS-2 CD133(+) enriched osteosarcoma cells. A) HFB grown SAOS-2
osteosarcoma cells (CD133+) are able to proliferate and assemble three-dimensionally as sarcosheres after 3-days of culture in the bioreactor (106
magnification). B) HFB grown SAOS-2 osteosarcoma cells (CD133+) are able to proliferate and assemble three-dimensionally as sarcosheres after 3-
days of culture in the bioreactor (406magnification). C) HFB grown SAOS-2 osteosarcoma cells (CD133+) seeded into an irradiated plastic culture
dish, reconstitute the normal attached phenotype of the parental SAOS-2 cells after one week of culture (106 magnification). Arrows point at
CD133(+) SAOS-2 cells showing a rounded and weakly attaching phenotype. D) HFB grown SAOS-2 osteosarcoma cells (CD133+) seeded into an
irradiated plastic culture dish, reconstitute the normal attached phenotype of the parental SAOS-2 cells after one week of culture (406magnification).
Arrow points at CD133(+) SAOS-2 cells showing a rounded and weakly attaching phenotype.
doi:10.1371/journal.pone.0010035.g004
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treatments, respectively. These phenomena may be due to the fact
that the cancer stem cells were stimulated to proliferate by culture
in the HFB environment. The CD133(+) cells that were not
subjected to the hypogravity environment appear to be resistant to
the same treatment regiment. Similar results were achieved by
treating the cells with the chemotherapeutic agents for 1 hour and
subjecting the samples to an MTT assay 24 hours later (data not
shown). These data have been confirmed with other techniques,
such as measurement of cell viability by trypan blue exclusion cell-
count before and after chemo treatment, as well as by flow-
cytometry analysis (data not shown).
Interestingly, the CD133(+) osteosarcoma cells had an overall
resistance to any dose of the cisplatin and methotrexate treatments
tested, whether above or below the assessed LD50. However, the
cancer cells stimulated to grow in the bioreactor, which are
CD133(+), showed enhanced cell death even at doses well-below
the LD50, suggesting that environments in which lack of gravity
Figure 5. Phase contrast images of spheres formed by MACSorted CD133(+) SAOS-2 osteosarcoma cells in ultra low-attaching
dishes. A) MACSorted CD133(+) SAOS-2 cells assemble three-dimensionally as sarcosheres after 2 weeks of culture in ultra low-attaching dishes (206
magnification). B) Another example of MACSorted CD133(+) SAOS-2 cells forming sarco-spheres after 2 weeks of culture in ultra low-attaching dishes
(106 magnification). C) SAOS-2 osteosarcoma cells deriving from three-dimensional cultures grown in ultra low-attaching dishes seeded into
attaching dishes show an adherent a differentiated phenotype after 3-days. D) SAOS-2 osteosarcoma cells deriving from three-dimensional cultures
grown in ultra low-attaching dishes seeded into attaching dishes show an adherent a differentiated phenotype after 5-days. E) SAOS-2 osteosarcoma
cells deriving from three-dimensional cultures grown in ultra low-attaching dishes seeded into attaching dishes show an adherent and differentiated
phenotype after 10 days.
doi:10.1371/journal.pone.0010035.g005
Table 3. Average number of colonies counted 6 standard
deviation in 6-well dishes in a triplicate experiment.
Parental SAOS-2 CD133(+) CD133(2)
Total number of colonies 120680 6406240 20612
doi:10.1371/journal.pone.0010035.t003
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2 cells. B) Contrast phase microscopy of a soft agar assay of HFB CD133(+) proliferated SAOS-2 cells. C) Propidium iodide flow cytometry analysis of
SAOS-2 cells grown in 1-G culture sorted by their CD133 status showing two distinct populations: the CD133(+) and CD133(2) cells with a different
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chemo treatments for patients.
Surprisingly, the CD133(+) osteosarcoma cells were sensitive to
treatments with doxorubicin even at doses lower than the LD50.
However, the CD133(+) cancer cells stimulated to grow in the
bioreactor showed enhanced cell death also at doses well-below the
clinically relevant doses that correspond to the LD50 for this drug.
We also investigated the apoptotic effect of the HFB on the
SAOS-2 cells by measuring the activity of caspases, using a
colorimetric caspases kit that measures the activity of caspases-3 in
the samples grown in the HFB for 5 days and treated with 10 mg/
mL of CDDP for 24 hours. Caspase-3 activity was measured 24-
hours after the chemotherapy treatment. We found that, according
to the data previously presented, the SAOS-2 cells cultured in the
HFB for 5 days showed an 4.5-fold increase of relative caspases-3
activity detected following CDDP treatment vs. the 3-fold of
increased caspases-3 activity detected in SAOS-2 cells treated with
the same amount of CDDP (10 mg/mL) in static growth condition.
This indicates that the HFB stimulated a CDDP-induced apoptosis
of the SAOS-2 cells (Figure 10).
The data presented here clearly show that the hypogravity
environment greatly sensitized the CD133(+) cells to various
chemotherapeutic agents. Importantly, we showed that the
CD133(+) cells, which are normally resistant to chemo treatment,
become sensitive even at low doses of the noxious drugs.
Discussion
Modeled hypogravity is a condition in which cells are able to
grow in an anchorage independent manner. The hydrofocusing
cell cycle profile. D) Immunophenotype of SAOS-2 cells grown in 1-G versus HFB culture showing that the SAOS-2 cells grown for 5 days in simulated
hypogravity contain the majority of the cells stained for Ki-67 and therefore in the S-phase of the cell cycle.
doi:10.1371/journal.pone.0010035.g006
Figure 7. Sensitivity of SAOS-2 cells to cisplatin following growth in simulated hypogravity. A)L D 50 for cisplatin determined for the
SAOS-2 cells. An LD50 of 10mg/mL for cisplatin was determined exposing the SAOS-2 cells to a 24-hours treatment using the MTT assay. Comparable
results were obtained with cell count by trypan blue exclusion. B) Histogram showing the sensitivity of SAOS-2 cells to 5mg/mL of cisplatin following a
24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy treatment, but the CD133(+) SAOS-2 cells proliferated and
selected with the HFB culture system are sensitive, instead. C) Histogram showing the sensitivity of SAOS-2 cells to a clinically relevant dose of 10mg/
mL of cisplatin following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy treatment, but the CD133(+)
SAOS-2 cells proliferated and selected with the HFB culture system are sensitive, instead. D) Histogram showing the sensitivity of SAOS-2 cells of
15mg/mL of cisplatin following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy treatment, but the
CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are sensitive, instead.
doi:10.1371/journal.pone.0010035.g007
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PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e10035Figure 8. Sensitivity of SAOS-2 cells to methotrexate following growth in simulated hypogravity. A)L D 50 for methotrexate determined for
the SAOS-2 cells. An LD50 of 22mg/mL for methotrexate was determined exposing the SAOS-2 cells to a 24-hours treatment to the drug, using the MTT
assay. Comparable results were obtained with cell count by trypan blue exclusion. B) Histogram showing the sensitivity of SAOS-2 cells to 4mg/mL of
methotrexate following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy treatment, but the CD133(+) SAOS-2
cells proliferated and selected with the HFB culture system are sensitive, instead. C) Histogram showing the sensitivity of SAOS-2 cells to 11mg/mL of
methotrexate following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy treatment, but the CD133(+) SAOS-2
cells proliferated and selected with the HFB culture system are greatly sensitive, instead. D) Histogram showing the sensitivity of SAOS-2 cells to a
clinically relevant dose of 22mg/mL of methotrexate following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the chemotherapy
treatment, but the CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are sensitive, instead. E) Histogram showing the
sensitivity of SAOS-2 cells to 45mg/mL of methotrexate following a 24-hours treatment, using an MTT assay. CD133(+) cells are resistant to the
chemotherapy treatment, but the CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are sensitive, instead.
doi:10.1371/journal.pone.0010035.g008
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PLoS ONE | www.plosone.org 12 April 2010 | Volume 5 | Issue 4 | e10035Figure 9. Sensitivity of SAOS-2 cells to doxorubicin following growth in simulated hypogravity. A)L D 50 for doxorubicin determined for
the SAOS-2 cells. An LD50 of 0.5mg/mL for doxorubicin was determined exposing the SAOS-2 cells to a 24-hours treatment to the drug, using an MTT
assay. Comparable results were obtained with cell count by trypan blue exclusion. B) Histogram showing the sensitivity of SAOS-2 cells to 0.25mg/mL
of doxorubicin following a 24-hours treatment, and using an MTT assay. CD133(+) cells are sensitive to the chemotherapy treatment, but the CD133(+)
SAOS-2 cells proliferated and selected with the HFB culture system are even more sensitive to the treatment, instead. C) Histogram showing the
sensitivity of SAOS-2 cells to 0.5mg/mL of doxorubicin following a 24-hours treatment, using an MTT assay. CD133(+) cells show sensitivity to the
clinically relevant dose of 0.5 mg/mL of doxorubicin, however the CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are
greatly sensitized to the chemotherapy treatment. D) Histogram showing the sensitivity of SAOS-2 cells to a dose of 1.1mg/mL of doxorubicin
following a 24-hours treatment, and using an MTT assay. The CD133(+) cells show sensitivity to a dose of 1.1mg/mL of doxorubicin, however the
CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are sensitized to the chemotherapy treatment. E) Histogram showing the
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NASA at the Johnson Space Center. The HFB is composed of a
50 mL fluid filled dome, which rotates at a specified speed to
provide a unique hydrofocusing capability, that in absence of gas
bubbles allows for a low-shear culture environment in which the
cells can grow in modeled hypogravity [25]. Another bioreactor
that allows cells to grow in a three-dimensional manner is the
rotatory cell culture system (RCCS) manufactured by Synthecon
(Houston, TX). The RCCS is a 50 mL horizontally rotating
culture vessel, which reduces the shear and turbulence generated
by conventional stirred bioreactors minimizing mechanical cell
damage and simulating aspects of hypogravity [25,26].
Prolonged exposure of humans and experimental animals to the
altered gravitational conditions of space flight has diverse effects
on various cellular systems [34,35,36,37,38,39]. However, the
effects of hypogravity on tumor growth and carcinogenesis are yet
unknown. The purpose of this study was to investigate the effects
of modeled hypogravity on cancer cell growth.
The existence of cancer stem cells in several solid
and hematopoietic tumors has recently been proven
[40,41,42,43,44,45,46,47]. Moreover, it was demonstrated that
cancer stem cells are also present in established cancer cell lines
[32,48,49].
Importantly, it is widely accepted that cancer stem cells are
responsible for tumor recurrence after chemo- or irradiation
therapy. Although it is still not clear whether the cancer stem
cells are derived from original tissue-derived stem cells, bone
marrow stem cells, or mature cells that have undergone a
dedifferentiation process, it has been suggested that novel
strategies for successful cancer therapy should focus on the
elimination of cancer stem cells [50].
Because osteosarcoma is a highly resistant tumor to conven-
tional therapies, we investigated whether osteosarcoma cell lines
contain a subpopulation of putative stem cells that could be
targeted for anti-cancer therapy. One of the biggest obstacles of
stem cell research results from the small number of stem cells
isolated from tissues. This limits research conducted on normal
adult stem cells as well as on cancer stem cells from liquid or solid
tumors. Of course, this issue may be overcome by in vitro
propagation of stem cells (cancerous or not) to obtain a sufficient
number of cells to develop novel therapies.
Stem cells have the potential to self-renew and generate a
developmental hierarchy of differentiating progeny. The original
culture methodology employed by Reynolds et al. [51] and
Reynolds and Weiss [52] to show that the adult mammalian brain
contains cells that give rise to neurosphere clones has been used to
isolate and characterize cells suspected of possessing attributes of
stem and progenitor cells. The Reynolds’ group showed that the
stressful growth conditions of their system due to serum starvation
allows dedifferentiation of certain cells, or selects for the most
sensitivity of SAOS-2 cells to 2.2mg/mL of doxorubicin following a 24-hours treatment, and using an MTT assay. CD133(+) cells are sensitive to the
chemotherapy treatment, but the CD133(+) SAOS-2 cells proliferated and selected with the HFB culture system are sensitive, instead.
doi:10.1371/journal.pone.0010035.g009
Figure 10. Graphic representation of the relative caspase-3 activity of SAOS-2 cells exposed to CDDP after growth stimulation in
simulated hypogravity. SAOS-2 cells grown for 5 days in the hydrofocusing bioreactor and treated with 10 mg/mL of CDDP die by apoptosis as
evidenced by a caspases-3 colorimetric assay. The white bar illustrates the caspase-3 activity recovered from SAOS-2 cells grown in the HFB and then
treated with CDDP for 24-hours. The black bar illustrates the caspase-3 activity recovered from SAOS-2 cells grown in static normal (1-G) condition
and then treated with CDDP for 24-hours, and the grey bar indicates the basal caspases-3 activity of SAOS-2 cells grown in static 1-G condition.
doi:10.1371/journal.pone.0010035.g010
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unable to survive.
In our study, the HFB on day 5 and day 7 increased CD133(+)
SAOS-2 cell growth compared to the RCCS vessel and to the
earth gravity control. We observed a (+)15-fold proliferation of the
SAOS-2 CD133(+) cellular fraction with cells that were cultured
for 7-days at optimized conditions in the HFB. The RCCS vessel
instead showed a (2)4.8-fold decrease in the CD133(+)cellular
fraction respect to the HFB after 7-days of culture. Additionally,
100% of the cells harvested from the HFB were found to be
CD133(+), indicating that the HFB had selected for the SAOS-2
undifferentiated cellular fraction. We speculate that the selective
growth of CD133(+) cells observed using the HFB vessel could be
due to its specific design. The presence of the conic spinner on the
axis of rotation of the HFB vessel that hydrofocuses the cell culture
allowing for a low-shear environment could be responsible of the
selective growth in the HFB environment.
In order to characterize and investigate the cells grown in the
HFB, we assessed the expression levels of various adhesion
molecules and stem cell markers before and after culturing the cells
in simulated hypogravity. The CD133(+) cells appeared healthy
and interestingly, both the expression levels and the number of
cells expressing several of the stem cell markers other than CD133
were increased after a seven-day run in the HFB. We found that
after a seven-day run compared to static growth control conditions
there were an increased number of SAOS-2 cells expressing
CD133, CD34, CD38, CD117/c-Kit, Sparc, Sox-9, RunX-2,
Stro-1, Osteocalcin, Endoglin, Integrin-ß1, and OCT3/4. The
fact that we found increased cell number of cells expressing the
tested markers and increased overall expression levels of the same
after culture of the cells in the hypogravity environment points
toward various scenarios. One scenario is that hypogravity could
epigenetically regulate the expression of genes involved in cell-cell
adhesion and migration, which are expressed during embryogen-
esis. Other possible scenarios are that hypogravity could affect
transcription or post-translational events such as proteasome
activity. We are currently analyzing a data set from a gene
expression microarray chip in which we studied osteosarcoma cells
challenged to grow in HFB versus cells grown in static 1-G in
order to better characterize the influence of hypogravity on
cellular homeostasis.
The importance of our work is summarized by the unique
ability of the HFB to proliferate cancer stem cells and to sensitize
them to low doses of chemotherapy. The selection of CD133(+)
SAOS-2 sub-population due to cell death of the CD133(2)
population is demonstrated by the activation of Caspase-3 activity
shown in figure 2 following culture of the SAOS-2 cells (total
population) in the HFB for 5-days.
We have also shown that the CD133(+) osteosarcoma cells,
which are chemo-resistant to the various drugs, became sensitive
to these same drugs at much lower doses than the LD50. In this
work we choose to test the effects of cisplatin, methotrexate and
doxorubicin on osteosarcoma cells, because those are the
commonly used drugs to combat this disease [53]. These drugs
have different mechanisms of action that can be recapitulated in
direct or indirect DNA damage. [54,55,56].
Current therapy for osteosarcoma includes neoadjuvant che-
motherapy, surgery, and postoperative (adjuvant) chemotherapy
[57,58]. Doxorubicin has been proven effective as adjuvant
chemotherapy regimens after surgery in preventing and/or
reducing recurrence and metastasis rates in osteosarcoma patients
that are operable [58,59]. Our findings that SAOS-2 cells in
general, and CD133(+) SAOS-2 cells in particular, are more
sensitive to doxorubicin than to cisplatin or methotrexate helps
elucidate some the clinical practice setting. However, more
importantly, we have demonstrated the existence of a chemo
sensitization switch operated by the hypogravity environment and
generated by the unique capabilities of the HFB vessel.
Using the HFB we have formulated a novel technique to select
and propagate CD133(+) cells. This will likely prove to be an
invaluable tool in furthering stem cell research, embryonic and
adult, as well as developing a rapid screening method to test
chemotherapeutic agents that are more affective against cancer
stem cells. Importantly, we showed that the HFB bioreactor
efficiently proliferated CD133(+) cells, while the RCCS rotating
vessel did not. Additionally, the data presented in this study clearly
show that the hypogravity environment, by stimulating CD133(+)
to proliferate, sensitized the CD133(+) to the various chemother-
apeutic agents tested.
Presently used chemotherapy drugs have a high rate of failure.
Cell culture chemotherapy testing is being used to identify which
drugs are more likely to be effective against a particular tumor
type in patients. Cell culture drug testing is of value in any
situation in which there is a choice between two or more
treatments. This includes virtually all situations in cancer
chemotherapy, whether the goal is cure or palliation. Often,
results are obtained before the patient begins treatment. This
kind of testing can assist in individualizing cancer therapy by
providing information about the likely response of an individual
patient’s tumor to proposed therapy. Presently, chemotherapy
testing is performed on cancer cells from patients without prior
separation and proliferation of the cancer stem cells from the
bulk of tumor cells. Knowing which chemotherapy agents the
patient’s cancer cells or cancer stem cells are resistant to is very
important. Then, these options can be eliminated, thereby
avoiding the toxicity of ineffective agents. Choosing the most
effective agent can help patients to avoid the physical, emotional,
and financial costs of failed therapy and experience an increased
quality of life.
Importantly, we showed that the HFB bioreactor proliferated
CD133(+) cells, which are the minority of the bulk of the tumor
cells. It is known that aggressive treatments destroy the majority of
the cancerous cells, however a small fraction of the cells, the
cancer stem cells, survive and often regenerate tumor cells that are
now chemo-resistant [23,24,60]. Therefore, to be able to test the
efficacy of cytotoxic agents in vitro prior to their use in clinical
setting on cancer cells as well as on cancer stem cells may pave the
way to more effective chemotherapeutic strategies in patients.
Materials and Methods
Cell culture
SAOS-2, HOS and U2OS (human osteosarcoma), T98G and
U87MG (human glioblastoma), Du145 and LNCap (human
prostate adenocarcinoma), WI38 and H23 (human lung fibroblast
and lung adenocarcinoma, respectively), Hep3b (human hepato-
carcinoma) and Hela (human cervical cancer) cells were obtained
by the American Type Culture Collection (ATCC, Manassas,
VA). Mewo and HO-1 cells (human melanoma) were kindly
provided by Dr. Paul B. Fisher (Virginia Commonwealth
University, VA) and HN12 and HN30 cells (human head & neck
squamous carcinoma) were kindly provided by Dr. George Yoo
(Wayne State University, MI). Cells were grown in the ATCC-
recommended medium (either RPMI 1640 or D-MEM) at 37uCi n
a water-saturated atmosphere of 95% air and 5% CO2. All media
were also supplemented with 2 mM L-glutamine and 10% fetal
bovine serum (Hyclone, Logan, UT), 100-mg/mL penicillin, 100-
mg /mL streptomycin (Invitrogen, Carlsbad, CA).
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A hydrodynamic focusing bioreactor (HFB) (Celdyne, Houston
TX) and a rotatory cell culture system (RCCS) (Synthecon,
Houston, TX) were used. Both vessels have a volume of 50 mL
and a membrane that allows for gas exchange. Culture media,
oxygenation, speed, temperature and CO2 were kept consistently
constant for the two culture systems, which were placed in the
same incubator. The vessels can rotate at adjustable speed on a
fixed axis. Cells were counted and a range of 1610
5–1.2610
7 cells
were placed in the 40 mL rotating chamber of the HFB for 3- to 7-
days set at 25 rpm with airflow set at 20%. For the RCCS, cells
were counted and the same number of cells was placed in the
50 mL rotating chamber for 3- to 7-days set at 25 rpm. Cells were
then removed and counted again using trypan blue exclusion to
determine cellular viability and cell number. The cells were either
pelleted for future research or labeled with florescent markers for
characterization.
Cell Sorting
Up to 2610
7 cells were sorted either by a magnetic-activated
cell sorting (MACS) system, which consists of magnetic beads
conjugated to an antibody against CD133 (Miltenyi, Auburn, CA),
or by flow cytometry (FACS Aria, BD Bioscience, San Jose, CA).
In brief, cells were harvested using 0.25% trypsin, pelleted and
labeled with CD133/1 biotin and CD133/2-PE. Cells were
washed and labeled with anti-biotin magnetic beads, and then
passed through a magnetic column where CD133(+) cells were
retained, while unlabelled cells passed through the column. The
CD133(+) retained cells were eluted from the columns after
removal from the magnet. Positive and negative cells were then
analyzed by FACS for purity.
Flow Cytometry studies
Cells were analyzed by the antigenic criteria using anti-CD133
(prominin1) (Milteny Biotech, Auburn, CA), -CD34 (Milteny
Biotech, Auburn, CA); -Sparc, -Sox-9, -RunX-2, -Osteocalcin,
-Integrin-ß1, -Endoglin, -Stro-1 (all from SantaCruz, Santacruz,
CA), -CD117/c-Kit (BD Bioscience, San Jose, CA), and –Oct3/4
(Cell Signaling, Danvers, MA). Briefly, cells were detached using
0.02% EDTA in PBS and pelleted (10 min at 1,000 rpm), washed
in 0.1% BSA in PBS at 4uC and incubated in a solution of 1mg
antibody +9 mL 0.1% BSA in 16PBS. Cells were washed in the
same solution once and were processed for sorting (FACS Aria,
BD Biosciences, San Jose, CA). Propidium iodide stained cells
were also analyzed with a fluorescence-activated cell sorter (FACS
Aria, BD Bioscience, San Jose, CA), and the data were analyzed
using the flow-Jo cell cycle analysis program (BD Biosciences, San
Jose, CA). Cell cycle was analyzed by flow cytometry as follows:
following staining with a primary antibody against CD133
(Milteny Biotec, Auburn, CA), and with the secondary antibodies
goat anti-mouse (FITC) and mouse anti-goat (PE conjugated)
(Santa Cruz, CA), cells were fixed in 4% paraformaldehyde for
30 min at room temperature, washed in PBS, then left for 60 min
in PBS/milk 6%. Then cells were stained with a DNA staining
solution (0.1% Triton X-100, 0.1% sodium citrate, 1 mg/mL
RNAse A and 50 mg/mL propidium iodide) for 2 h at room
temperature in the dark. Isotypes and non-probed cells were used
as controls. Multiple cell cycle analysis studies were performed to
obtain a reproducible model experiments on growing cells.
Annexin-V assay
Annexin-V was analyzed with the Annexin-V/FITC Kit
(Bender MedSystems, Burlingame, CA) following manufacturer’s
instructions. Cytometry was operated with a FACS Aria (BD
Bioscience, San Jose, CA).
Soft agar assay and sphere assay
Cells were counted and 5610
3 SAOS-2 and CD133 (+) and (2)
SAOS-2 cells were plated in 6-well culture dishes in 3 mL of soft
agar growth medium; 500 mL of medium per well were added
every 2 days.
Formed spheres were counted under the microscope. Cells were
also plated in ultra-low attachment dishes (Corning, Lowell, MA
catalogue# 3262), and the number of spheres for each well was
evaluated after 7 and 14 days of culture. The ultra-low attachment
surface has a neutral hydrophilic hydrogel coating, which greatly
reduces binding of attachment proteins. This minimizes cells
attachment and spreading.
Immunofluorescence
2610
4 cells were seeded on two-well micro-chamber slides
(Nunc, Naperville, IL). On the day cells were stained, they were
washed with PBS and blocked in a mixture of 0.5% BSA, 2 mM
EDTA, and FcR blocking reagent (Miltenyi, Auburn, CA) for
20 minutes. The primary antibodies were incubated for 20 min-
utes on ice, washed with PBS twice, and a secondary anti-mouse or
anti-rabbit conjugated with Fitc or PE (e-Bioscience, San Diego,
CA) antibodies were used at a dilution of 1:200 and were
incubated on ice for 15 minutes. Negative controls were
performed with secondary antibodies only. The slides were viewed
under an inverted Olympus IX70 microscope (Olympus America,
Inc., Melville, NY). Fluorescence images were captured with
Sensicam QE camera (Cooke Co., Auburn Hills, MI) and
operated with SlideBook 3.0 software (Intelligent Imaging
Innovations Inc., Denver, CO).
In vitro growth characteristics and chemosensitivity
To determine the in vitro growth rate of each cell line, 30,000
cells/cm
2 w e r es e e d e di nt h ea p p r o p r i a t et i s s u ec u l t u r em e d i a .
Cells were then harvested and counted by Trypan blue dye
exclusion every 24 h, and doubling time was calculated during
the exponential phase of growth (from 48 to 96 h after seeding).
For saturation density, from day 4 onwards, the medium was
changed daily, and cells were counted every 2 days until they
stopped growing. LD50 was calculated by assessing cell viability
using trypan blue exclusion staining and confirmed by MTT
assay. Cisplatin (Alexis Biochemicals, San Diego, CA), Doxo-
rubicin (Sigma Aldrich, St. Louis, MO) and Methotrexate (MP
Biomedicals, Solon, OH) were dissolved to a stock concentration
of 100 mg/mL, 50 mg/mL, and 20 mg/mL, respectively and
diluted in normal saline immediately before the experiments.
Cells were treated with the chemotherapeutic agent for 1 hour,
and then were washed and fresh culture medium was added.
Cell viability was assessed 24 hours after treatment. Cells were
also treated continuously for 24 hours with the chemothera-
peutic agent, and their viability was assessed after treatment.
The degree of cisplatin, doxorubicin, and methotrexate
resistance was expressed by the drug concentration resulting
in 50% inhibition of viability (LD50)o ft h ev a r i o u sc e l ll i n e s .T o
determine the LD50 values 30,000 cells/cm
2 were seeded in
their growth medium containing 10% FBS, and after 24 h the
medium was replaced with medium containing 10% FBS and no
drug (control) or with different concentrations of the chemo-
therapy drugs. After 96 h, cells were harvested and counted by
Trypan blue dye exclusion to estimate the percentages of cell
death compared with the appropriate control, which were then
used to calculate the LD50 values.
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1610
4 exponentially growing cells were seeded in 100 mLo f
medium in 96-microwell, flat-bottomed plates. For each of the
variants tested, 7 repeats were used. Following 24 hr in culture (to
allow the cells to attach and resume growth), 20 mL of different
concentrations of the drug were added to each well containing
untreated cells. Normal saline was added to the controls. Cells
were exposed to the drugs either for 24-hours continuously or for
one hour time intervals, as indicated. At the end of drug exposure,
the CDDP- MTX or DOX-treated cells as well as parallel control
cells were incubated for 4 hours with 50 mL of MTT solution
(5 mg/mL). After incubation, culture medium in each well was
discarded and replaced with 50 mL of DMSO. After 10 minutes
shaking, the absorbance of each well was determined by a
spectrophotometer at 510 nm wavelength. The percentage of cell
viability was calculated by multiplying the ratio absorbance of the
sample versus the control by 100. Chemotherapeutic drugs’ LD50
was determined as a chemotherapeutic drugs’ concentration
showing 50% of cell survival as compared with the control cells.
The experiments were repeated in seven replicates.
Caspase-3 colorimetric assay
Caspase-3 activity was measured with a Caspases-3 colorimetric
assay kit (Chemicon, (now Millipore, Billerica, MA) following
manufacturer’s instructions.
Statistics
The results for each variant in the different experimental
designs represent an average of 4 to 5 different experiments. The
data of 7 or more measurements were averaged; the coefficient of
variation among these values never exceeded 10%. Mean values
and standard errors were calculated for each point from the
pooled normalized to control data. Statistical analysis of the
significance of the results was performed with a 1-way ANOVA.
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